Australia markets closed

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.2450-0.0110 (-4.30%)
At close: 03:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.31M
Enterprise value 27.50M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.99
Price/book (mrq)N/A
Enterprise value/revenue 12.10
Enterprise value/EBITDA -4.88

Trading information

Stock price history

Beta (5Y monthly) -0.07
52-week change 3-73.40%
S&P500 52-week change 323.06%
52-week high 31.0400
52-week low 30.1400
50-day moving average 30.2160
200-day moving average 30.3449

Share statistics

Avg vol (3-month) 393.42k
Avg vol (10-day) 351.5k
Shares outstanding 525.74M
Implied shares outstanding 625.74M
Float 821.57M
% held by insiders 11.14%
% held by institutions 10.03%
Shares short (30 Mar 2012) 46.34k
Short ratio (30 Mar 2012) 43
Short % of float (30 Mar 2012) 43.64%
Short % of shares outstanding (30 Mar 2012) 42.38%
Shares short (prior month 29 Feb 2012) 4107

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 305 June 2017
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 305 June 2017

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-313.02%

Management effectiveness

Return on assets (ttm)-212.70%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2.27M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)186.70%
Gross profit (ttm)N/A
EBITDA -7.42M
Net income avi to common (ttm)-29.56M
Diluted EPS (ttm)-1.5800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.26k
Total cash per share (mrq)0
Total debt (mrq)21.2M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.03
Book value per share (mrq)-1.22

Cash flow statement

Operating cash flow (ttm)-3.48M
Levered free cash flow (ttm)-15.02M